Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, 10 November 2023.
Year of Publication2023
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
Originally developed
We recommend not to use ivermectin in patients with severe or critical COVID-19, except in the context of a clinical trial
Recommended against
Strong
Certainty of evidence
Very low
Notes and Remarks
Remarks
- A recommendation to only use a drug in the setting of clinical trials is appropriate when there is very low certainty evidence and future research has a large potential for reducing uncertainty about the effects of the intervention and for doing so at reasonable cost.
- A strong recommendation against use of ivermectin in patients with non-severe COVID-19 was published in October 2023, given new trial evidence.
Also Featured In
This recommendation also appears in the following guidelines:
Guideline
Therapeutics and COVID-19: living guideline, August 2025
Year2025
InstitutionWorld Health Organization